Centogene Extends Genetic Testing Partnership With Takeda

By Chris Wack

Centogene N.V. said Tuesday that it has extended its partnership with Takeda Pharmaceutical Co. to diagnose patients with Lysosomal Storage Disorders.

Under the renewed one-year partnership agreement, Centogene will continue to provide Takeda with access to diagnostic testing for patients around the world.

The aim of the commercial fee-for-service agreement is to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease and Hunter syndrome.

In January 2015, Centogene originally entered into an agreement with Shire Pharmaceuticals, which was bought in 2019 by Takeda, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from rare genetic diseases. Last year, the contract was extended until March 2023.

Centogene shares were up 15% at 75 cents in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

April 11, 2023 07:05 ET (11:05 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.